Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
Background. Chronic hepatitis C infection is a major cause for liver failure and liver cancer and can be treated with highly effective all oral directly acting antiviral (DAA) drugs. Generic versions of these DAAs are available in India. Method. This was an open-label, single-center, prospective, no...
Saved in:
Main Authors: | L. Tang, M. Kamat, A. Shukla, M. Vora, C. Kalal, S. Kottilil, S. Shah |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Interdisciplinary Perspectives on Infectious Diseases |
Online Access: | http://dx.doi.org/10.1155/2018/9124604 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
by: Hirokazu Suii, et al.
Published: (2017-01-01) -
Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
by: Anna Maruyama, et al.
Published: (2016-01-01) -
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection
by: Yong-yu Mei, et al.
Published: (2020-01-01) -
Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
by: Jiayi Wang, et al.
Published: (2024-12-01) -
Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic review and meta-analysis
by: Liwei Zhuang, et al.
Published: (2025-02-01)